Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 3 Univariate and multivariate cox analyses of PFS for ES-SCLC patients receiving ICIs

From: Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis

Variables

Univariate analysis

Multivariate analysis

HR (95% CI)

P value

HR (95% CI)

P value

Gender

    

 Male

    

 Female

0.608 (0.390–0.946)

0.027*

0.586 (0.374–0.917)

0.019*

Age

    

 ≥ 60

    

 < 60

0.999 (0.707–1.410)

0.994

  

Smoking History

 Yes

    

 No

0.785 (0.552–1.116)

0.177

  

ECOG PS

  2

    

 ≥ 2

1.266 (0.845–1.898)

0.253

  

T stage

 ≤ 2

    

 > 2

1.603 (1.132–2.272)

0.008*

1.778 (1.240–2.550)

0.002*

N stage

 ≤ 2

    

 > 2

1.596 (1.121–2.270)

0.009*

1.436 (0.998–2.066)

0.051

M stage

 M1a

    

 M1b

1.096 (0.681–1.764)

0.705

  

 M1c

1.866 (1.706–3.293)

0.026*

1.956 (1.117–3.424)

0.019*

Type of ICIs

 PD-1

    

 PD-L1

1.718 (1.156–2.554)

0.007*

1.684 (1.120–2.533)

0.012*

Receiving TRT

 No

    

 Yes

0.651 (0.460–0.920)

0.015*

0.599(0.420–0.854)

0.005*

NO. of metastatic sites

 < 3

    

 ≥ 3

1.605 (0.917–2.808)

0.098

  

Liver metastases

 No

    

 Yes

1.192 (0.798–1.780)

0.391

  

Bone metastases

 No

    

 Yes

1.409 (0.964–2.060)

0.077

  

Brain metastases

 No

    

 Yes

1.039 (0.719–1.502)

0.838

  
  1. PFS, progression-free survival; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ICIs, immune checkpoint inhibitors; TRT, thoracic radiotherapy; NO., number; HR, hazard ratio; CI, confidence interval; *P < 0.05